COMMITMENTS AND CONTINGENCIES (Details 2) (USD $)	3 Months Ended								12 Months Ended							12 Months Ended								0 Months Ended	12 Months Ended	0 Months Ended	3 Months Ended	12 Months Ended	0 Months Ended		12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012 License agreement	Dec. 31, 2011 License agreement	Dec. 31, 2010 License agreement	Dec. 31, 2012 License agreement JHU	Dec. 31, 2012 License agreement MAYO	Dec. 31, 2011 License agreement MAYO	Jun. 12, 2013 License agreement MAYO	Jun. 12, 2012 License agreement MAYO	Sep. 30, 2011 License agreement MAYO Warrant covering 1,000,000 shares of common stock	Jun. 30, 2011 License agreement MAYO Warrant covering 1,000,000 shares of common stock	Sep. 30, 2010 License agreement MAYO Warrant covering 1,000,000 shares of common stock	Jun. 11, 2009 License agreement MAYO Warrant covering 1,000,000 shares of common stock	Jun. 11, 2009 License agreement MAYO Warrant covering 250,000 shares of common stock	Dec. 31, 2012 License agreement MAYO Warrant covering 250,000 shares of common stock	Oct. 14, 2009 License agreement Hologic	Jun. 30, 2011 License agreement Hologic	Dec. 31, 2012 License agreement Hologic	Jul. 26, 2010 License agreement MDx Health	Dec. 31, 2012 License agreement MDx Health	Dec. 31, 2012 License agreement MDx Health Net sales of $ 10 million	Dec. 31, 2012 License agreement MDx Health Net sales of $ 50 million	Dec. 31, 2012 License agreement MDx Health Net sales of $ 50 million	Dec. 31, 2012 Clinical research agreements	Dec. 31, 2011 Clinical research agreements	Dec. 31, 2010 Clinical research agreements
Commitments and contingencies
Annual minimum license fee agreed to be paid by the entity															$ 100,000
Upfront payment																										50,000
Amount paid upon enrollment in FDA trial																											100,000
Minimum royalty payments																		25,000	10,000
Number of shares of common stock covered by warrants																				250,000	500,000	800,000	1,000,000	250,000
Vesting period of warrant (in years)																								4 years	4 years
Period for recognition of related expenses																								4 years	4 years
Milestone payment contingent upon FDA approval																500,000												100,000	100,000
Minimum royalty fee that the entity is required to pay on each anniversary																														100,000
Amount agreed to be paid upon the first commercial sale of a licensed product																														100,000
Amount agreed to be paid upon reaching the specified amount of net sales																															150,000	750,000	1,000,000
Net sales of a licensed product																															10,000,000	50,000,000	50,000,000
Research and development expense	10,439,000	10,491,000	12,202,000	8,999,000	7,672,000	6,110,000	5,197,000	2,989,000	42,131,000	21,968,000	9,023,000	1,400,000	800,000	400,000		1,200,000	1,400,000																	1,200,000	1,000,000	1,300,000
Future minimum payments due under the entity's technology licenses
2013	496,000								496,000
2014	296,000								296,000
2015	296,000								296,000
2016	256,000								256,000
2017	256,000								256,000
Thereafter	2,288,000								2,288,000
Total	$ 3,888,000								$ 3,888,000